In honor of National Donate Life Month, columnist Sam Kirton shares his story about the impact of receiving a lung transplant ...

The FDA has approved Cipla's nintedanib capsules as a new generic version of Ofev for treating idiopathic pulmonary fibrosis ...

The PFF's strategic plan includes several initiatives to make the community more inclusive of all forms of ILD, writes columnist Sam Kirton.

An IPF diagnosis left columnist Sam Kirton feeling lost, but thanks to several "navigation tools," he eventually found his way.

A compound called orcinol glucoside (OG) can reduce lung inflammation and scarring in mouse and cell models of idiopathic pulmonary fibrosis (IPF), according to the findings of a new study, which ...

In 2019 Christie Patient relocated to San Francisco to care for her mother, Holly, before and after her double-lung transplant. Holly’s idiopathic pulmonary fibrosis diagnosis came only months before ...

On New Year’s Day, my daughters and I created vision boards for 2026. If you haven’t made one before, a vision board is a collage of images, quotes, and art that captures your goals and intentions for ...

Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in an early Phase 2a clinical trial, according to new data ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google Over the holidays, for the first time in a long while, my home ...

The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring ...

Building on positive Phase 2 data, Puretech Health plans to launch a Phase 3 trial in the coming months to further test its experimental oral therapy deupirfenidone (LYT-100) in people with idiopathic ...

Rein Therapeutics is working with clinical sites to begin recruiting patients in the U.K. for its Phase 2 trial of LTI-03, a therapy candidate for idiopathic pulmonary fibrosis (IPF), after receiving ...